Sfoglia per AUTORE
POMPA A
Collezione AOU Novara
Items : 2
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials. in Haematologica / Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251.
2024
AOU Città della Salute di Torino
AOU Novara
AOU Città della Salute di Torino
AOU Novara
Ferretti E; Sgherza N; Rizzi R; Cotzia E; Gozzetti A; Rossini B; Bongarzoni V; Amendola A; Fontana R; Amico V; Accardi F; Brunori M; Vincelli D; Pompa A; Palumbo G; Barilà G; Uccello G; Ria R; Rago A; Casaluci GM; Tarantini G; Offidani M; Di Renzo N; Mele G; Cerchione C; Conticello C; Musso M; Califano C; Zamagni E; et alii...
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase? 2 trial. in Blood cancer journal / Blood Cancer J. 2022 Jan 24;12(1):9. doi: 10.1038/s41408-021-00593-2.
2022
AOU Novara
AOU Novara
Dimopoulos MA; Schjesvold F; Doronin V; Vinogradova O; Quach H; Leleu X; Montes YG; Ramasamy K; Pompa A; Levin MD; Lee C; Mellqvist UH; Fenk R; Demarquette H; Sati H; Vorog A; Labotka R; Du J; Darif M; Kumar S;